Podcast appearances and mentions of Charles River

Founded in 2010, the Institut Pasteur spinout PathoQuest sold to top CRO Charles River for $70M this year, a product of years of collaboration and stepwise investments.Jean‑François tells us how the exit unfolded, as well as the importance of biosafety and CMC as pharma and biotech outsource heavily and cell and gene therapies mature. We also cover how animal testing is disappearing from CMC and how France must nurture its biotech ecosystem.---For transparency, this episode has been sponsored by PathoQuest.---⭐️ ABOUT THE SPEAKERJean-François has more than 20 years of pharma leadership under his belt. Before his ten years at PathoQuest, he was a Senior Vice-President in charge of Ipsen's GI-oncology and endocrinology franchise.He has an engineering degree and a master's degree in Foreign Trade.

In this episode, Fred interviews Steve Watson - Author of: All Flesh Shalom: Larger, Freer, More Loving Readings of the Good News of Jesus.   Learn more at:   https://allfleshshalom.substack.com/   https://www.reservoirchurch.org/staff/steve-watson-3/   https://a.co/d/05bZdYNx   About Steve:   Steve Watson has been the senior pastor of Reservoir Church since July, 2013. Prior to that, he served as the principal of Watertown High School and as a middle- and high-school English teacher in the Boston Public Schools. Steve is also active as a leader in interfaith community organizing for public justice and on the integration of healthy faith and mental health. He serves on the Board of the Greater Boston Interfaith Organization, is a regional area developer with the Post-Evangelical Collective, and is a past board member of Samaritans. Steve has a B.A. in music from Brandeis University, a Masters in Education from UMASS-Boston, and a Doctorate in Theology and Ministry, through the Center for Open and Relational Theology at Northwind Seminary.   Born and raised in eastern Massachusetts, Steve has traveled extensively but has never left behind his great affection for the Charles River, the Red Sox, and (almost) all things New England. Steve and his wife Grace, a government policy analyst, became members of Reservoir Church in 2006. They love this community's accessibility, authenticity, and vibrant connection with a living God. Beyond Reservoir and his family, Steve also loves hiking and walking in the woods, reading fiction and theology, and singing with his Renaissance choir, Convivium Musicum.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest news shaping the industry, from breakthroughs in cancer therapies to advancements in AI-driven drug discovery. Starting with regulatory updates, the potential appointment of Richard Pazdur, M.D., as the new FDA Commissioner is causing quite a stir. Following Marty Makary's resignation, Pazdur has emerged as a prominent candidate due to his extensive background in oncology drug regulation. Known for his commitment to accelerating cancer therapy approvals, his potential leadership could maintain or even amplify the focus on expediting innovative treatments for cancer patients. In a significant regulatory achievement, Beone Medicines celebrated the FDA's approval of Beqalzi, marking it as the first BCL-2 inhibitor approved for mantle cell lymphoma. This approval challenges AbbVie's Venclexta and underscores a growing trend towards targeted cancer therapies that offer new treatment avenues for patients. The oncology space continues to be fiercely competitive, with companies striving to deliver more precise and effective cancer treatments. Turning to clinical trials, AstraZeneca's Imfinzi has shown promising results in a phase 3 trial focused on bladder cancer patients who are not eligible for cisplatin-based chemotherapy. These findings position Imfinzi as a strong competitor to Merck's Keytruda and reinforce AstraZeneca's strategic focus on expanding its oncology portfolio through novel combinations and indications. In the realm of genetic therapies, Regenxbio has achieved a milestone with its gene therapy for Duchenne muscular dystrophy. This therapy met its primary endpoint in pivotal trials, highlighting the potential of gene therapies to address rare diseases with limited treatment options. Such successes are likely to encourage further investment in gene editing technologies, which hold significant promise for tackling conditions once deemed untreatable. The FDA is also exploring frameworks to repurpose existing drugs for new uses by leveraging existing safety data. This could streamline drug development processes and offer cost-effective solutions for patients with complex conditions. However, this approach will need rigorous validation of efficacy in new indications to ensure patient safety and therapeutic effectiveness. Despite setbacks in its Alzheimer's research, Biogen remains steadfast in its efforts. While their tau-targeting candidate did not meet primary endpoints in a phase 2 trial, reductions in tau pathology and cognitive benefits were observed. This perseverance showcases Biogen's commitment to finding innovative approaches to tackle Alzheimer's disease despite ongoing challenges. On the operational front, Taiwan's Bora Group is acquiring Macrogenics' CDMO operations for up to $127.5 million. This move reflects a broader trend of consolidation within the CDMO space as companies aim to enhance their production capabilities and streamline operations. Quality control remains a critical concern as evidenced by Sun Pharma's recent recall of a chemotherapy batch due to glass particle contamination. Incidents like these underline the importance of stringent quality assurance measures throughout the manufacturing process to ensure patient safety. Moreover, Viz.ai has launched an AI-powered pulmonary care platform aimed at integrating acute and chronic care workflows. This development signals an increasing adoption of artificial intelligence in healthcare, promising improvements in diagnostics and patient management efficiency. AI continues to gain traction as Isomorphic Labs recently secured $2.1 billion in Series B funding aimed at enhancing AI-driven drug design models. Similarly, Charles River has introduced an AI-powered digital pathology platform poised to Support the show

Monday afternoon chaos erupted when a 46-year-old man carrying a rifle started walking down Memorial Drive in Cambridge and randomly opened fire towards people along the Charles River and motorists driving by. The shooter is believed to have shot between 50-60 rounds before being shot by a state trooper and a Marine veteran. Two drivers were shot and critically injured. We discussed the latest on this incredibly dangerous situation that erupted on Memorial Drive, that some witnesses are describing as being like a video game with the gunman “shooting all over the place” and “blood everywhere.”See omnystudio.com/listener for privacy information.

Monday afternoon chaos erupted when a 46-year-old man carrying a rifle started walking down Memorial Drive in Cambridge and randomly opened fire towards people along the Charles River and motorists driving by. The shooter is believed to have shot between 50-60 rounds before being shot by a state trooper and a Marine veteran. Two drivers were shot and critically injured. We discussed the latest on this incredibly dangerous situation that erupted on Memorial Drive, that some witnesses are describing as being like a video game with the gunman “shooting all over the place” and “blood everywhere.”See omnystudio.com/listener for privacy information.

The 18 Americans who were aboard a hantavirus-stricken cruise ship have returned to the U.S. and are now in quarantine. A gunman opens fire at passing cars along the Charles River near Boston. And, a CBS News exclusive. Kirk Moore, an Oklahoma high school principal, took a bullet tackling a gunman in his school's lobby. He told CBS News what he did was "just instinct" and said he didn't even realize he'd been shot at first. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Motorists in Cambridge, Massachusetts were running for cover Monday when a man opened fire along the Charles River. The AP's Jennifer King reports.

Send us Fan MailSend us Fan MailIn 1982, having sold his jazz bar to devote himself to writing, Murakami began running to keep fit. A year later, he'd completed a solo course from Athens to Marathon, and now, after dozens of such races, not to mention triathlons and a dozen critically acclaimed books, he reflects upon the influence the sport has had on his life and—even more important—on his writing. Equal parts training log, travelogue, and reminiscence, this revealing memoir covers his four-month preparation for the 2005 New York City Marathon and takes us to places ranging from Tokyo's Jingu Gaien gardens, where he once shared the course with an Olympian, to the Charles River in Boston among young women who outpace him. Through this marvelous lens of sport emerges a panorama of memories and insights: the eureka moment when he decided to become a writer, his greatest triumphs and disappointments, his passion for vintage LPs, and the experience, after fifty, of seeing his race times improve and then fall back. By turns funny and sobering, playful and philosophical, What I Talk About When I Talk About Running is rich and revelatory, both for fans of this masterful yet guardedly private writer and for the exploding population of athletes who find similar satisfaction in running.Link for 20% discount on Caffeine Bullet  https://caffeinebullet.com/RUNNINGBOOK Discount automatically applied and visible on checkoutSupport the showAny feedback or suggestions on this review or any of our other podcast episodes would be greatly welcomed. Leave us a review using your favorite podcast player or contact us on social media.Facebook: https://www.facebook.com/runningbookreviews/Twitter: https://twitter.com/reviews_runningInstagram: https://www.instagram.com/runningbookreviews/Podcast webpage: https://runningbookreviews.buzzsprout.com  If you have been enjoying the podcast and want more, you can find some extras on our By Me a Coffee site! https://www.buymeacoffee.com/runningbookreviewsLink for 20% discount on Caffeine Bullet https://caffeinebullet.com/RUNNINGBOOK Discount automatically applied and visible on checkoutSupport the showAny feedback or suggestions on this review or any of our other podcast episodes would be greatly welcomed. Leave us a review using your favorite podcast player or contact us on social media.Facebook: https://www.facebook.com/runningbookreviews/Twitter: https://twitter.com/reviews_runningInstagram: https://www.instagram.com/runningbookreviews/ Podcast webpage: https://runningbookreviews.buzzsprout.com  If you have been enjoying the podcast and want more, you can find some extras on our By Me a Coffee site! https://www.buymeacoffee.com/runningbookreviews

"It felt so good to be reminded of all the reasons I love to do this." There's nowhere I'd rather be on the third Monday in April than at the Boston Marathon finish line! This year, I was honored to be asked back to perform a variety of roles in Boston. I hosted a panel at the Expo along with two live shows. I was one of the race announcers at the finish line on Marathon Monday, and I was the finish line reporter for the world feed broadcast. It was a big, busy, fun, rewarding weekend that included quality time with my favorite people, a million finish line hugs, a quick meet-and-greet with a former President, a few too many late nights, and so much more. Best Boston ever? Best Boston ever. (Please know that I am genuinely horrified by how long this solo recap ended up being! Someone take the microphone away from me!) SPONSOR:  Vuori: Click here for 20% off your first Vuori purchase. IN THIS EPISODE Why this year's Boston Marathon weekend was extra meaningful for me, and what it took to get there (1:45) Thursday: the drive to Boston, the Official Program reveal, and the best burger of my life (9:10) Friday: the press conference, the Expo panel, the WBUR live show with Claire Holt, and the New Balance party (14:10) Saturday: cheering for the 5K, the New Balance live show, and making my "indoor debut" at the New Balance Marathon Relay (48:05) Sunday: a Charles River run, broadcast meetings, and a night out with the Citius crew (1:18:25) Marathon Monday: a picture-perfect day at the finish line (1:30:10) Tuesday: time to go home (2:15:10) Follow Ali: Instagram @aliontherun1 Join the Facebook group Support on Patreon Subscribe to the newsletter SUPPORT the Ali on the Run Show! If you're enjoying the show, please subscribe and leave a rating and review on Apple Podcasts. Spread the run love. And if you liked this episode, share it with your friends!

WBZ NewsRadio's Shari Small reports.See omnystudio.com/listener for privacy information.

Michael Phelps, the swimming legend with 28 Olympic medals, just added another glittering chapter to his post-pool legacy. On April 21, Forbes presented him with the Under 30 Role Model Award during a high-profile summit, honoring not just his record-breaking golds but his raw, transformative push for mental health awareness. In a candid onstage chat captured on Forbes YouTube, Phelps dished on everything from that wild 2016 Under 30 Summit run along the Charles River that drew 7000 fans, to the brutal mental grind of Rio where he finally tuned into his well-being like never before, feeling like a kid again on the blocks. He got real about building a trusted team over his 20-year career, evolving habits under insane pressure, and smashing stigma by admitting as a male athlete how tough it was to ask for help—heartbreaking stuff that could save lives.No fresh headlines in the last 24 hours, but this award buzzes with long-term bio gold: it cements Phelps as a beyond-sport icon, bridging his aquatic dominance to inspiring the next gen against mental health shadows. Social media's quiet on direct mentions from him lately, no verified business moves or public pops since, though whispers of his coaching insights ripple through swim pods—no confirmed deets there. All verified, no gossip fumes.Thanks for listening, subscribe to never miss an update on Michael Phelps and search the term Biography Flash for more great Biographies. This has been a Quiet Please production.This content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

8:05PM: American Lung Association State of the Air report. What grade did the Boston Metro area receive for air quality? Guest: Daniel Fitzgerald – Director of Advocacy for RI & MA with the American Lung Association 8:15PM: As the highly anticipated 2026 summer travel season approaches, consumer behavior is shifting, and the way Americans travel is changing. How? Are Americans pulling back on travel, or simply adjusting? What’s the #1 tip for saving money and avoiding hassles? Guest: Regina Lewis - Consumer Analyst and Travel Industry Expert 8:30PM: This year marks the 30th anniversary of Gov. Bill Weld’s jump into the Charles River promoting healthy water! How is the Charles River’s health today? The 27th Annual Charles River Earth Day Cleanup is happening this Friday April 24 & Saturday April 25! How can people get involved? Guest: Laura Jasinski, Executive Director of the Charles River Conservancy 8:45PM: Crypto/AI scammers are zeroing in on America’s seniors, with the losses exploding. How scammers groom and manipulate elderly victims and the red flags families need to know before it’s too late! Guest: Courtney Werning – Principal attorney at Meyer Wilson WerningSee omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.

We are joined by retiring CEO Jim Foster to discuss his 50 year career at Charles River. Through his decades in the industry, Foster has seen it all - from the shift toward new approach methodologies, through mergers and sales and public offerings, to shaping the future of Charles River's culture. Listen now to hear how it all started, how we got here, and where we are heading in the future.

Bryan and Peter catch up with longtime friend of the show and owner of Charles River Running Company, Charolotte Walsh. After 14 years, Charlotte has made the decision to close her store in Norwood, MA and focus on a new business endeavor. She discusses camping and hiking in Maine, what factored into her closing the shop, and reveals what she will be doing next. You can listen to our original 2017 interview with Charlotte on HWYRT Episode 89. https://dts.podtrac.com/redirect.mp3/dts.podtrac.com/redirect.mp3/traffic.libsyn.com/secure/howwasyourruntoday/HWYRT_89.mp3 For more about Charlotte, her store, and her running club please visit https://charlesriverrunning.com/ Please visit OUR site at www.HWYRT.com and be sure to tell us if you will be taking part in the upcoming 2026 This Would Have Been Shorter Tomorrow Summer Solstice Run at https://hwyrt.com/twhbst/ or just send us a and email with a Voice Memmmooooo at howwasyourruntoday@gmail.com  

Buckle up because it's time for Ep. 65 of the Between 2 Brands #podcast with your host, Bill Petrie. In the Opening Shot, Bill talks about what one regional association is doing to completely flip the standard script on driving membership value – and it's amazing. After that, he is joined by the Vice President of Sales of Charles River, Lindsey Davis. During a wide-ranging chat, they discuss working for family-owned companies, navigating the sale of a business and transitioning to working for the purchaser, and lessons in sales leadership. It's a really engaging conversation and one that's truly worth listening to. BIG thanks to our pals over at Seven Sourcing for sponsoring this fine broadcast. When you're ready to be the partner your clients want – one that delivers unique, custom, and bespoke branded merch designed exclusively for them – reach out to Russ and his team at sales@sevensourcing.com.

I am joined by Charles River's newest Senior Vice President, Chief Scientific & Innovation Officer Dr. Namandjé Bumpus to discuss her amazing career. From hands on research as Professor and Director of the Department of Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine, to Chief Scientist and later Principal Deputy Commissioner at the US Food and Drug Administration, Dr. Bumpus has seen every angle of the industry. She joins me to discuss her research, the discipline she learned from her father's boxing gym, and her perspective on the industry today. 

THIS IS THE 'SEVERED: ORIGINS' BREAKDOWN OF 'ETERNAL SUNSHINE' - PT02Welcome back for Part Two of this ultimate breakdown of "Eternal Sunshine of the Spotless Mind." We're headed to the Charles River for a 'Honeymoon on Ice.' Joel and Clementine, against all odds, are once again an item. We're also going to get to the offices of Lacuna, Inc...the mind wipe guys! This ORIGINS entry is a trippy 2004 title from French Director Michel Gondry. Both Dan Erickson and Ben Stiller list it as an inspiration. It stars Kate Winslet and Jim Carrey. This is considered one of the best things Jim Carrey has ever done.Get ready for Part TWO of this enormous movie breakdown.*******Huge thanks to Adam Scott, star of 'Severance' and host of the Severance Podcast for recording a custom intro for "Severed." Make sure to check out 'The Severance Podcast w/Ben Stiller & Adam Scott" wherever you found this one!A big 'thank you' to friend of the pod Kier Eagan, er I mean Marc Geller! Marc both sat for an interview (make sure to check it out) AND recorded some great bumpers as Kier himself. Follow Marc on Instagram @geller_marc.BIG Thanks to Friend of the Podcast Hayley Erickson-Goelzer. She is Sister to creator Dan Erickson and also a listener. It took getting approval from Dan's Press Person, but thanks to her follow-through we've got a custom bumper from Hayley Erickson-Goelzer!!Yes, that is really and truly Primary Director and Executive Producer Ben Stiller doing a custom bumper for 'Severed.' He actually did this bumper for the show while we were recording an interview for the Official Ben & Adam Podcast. Thank you, Ben for the Bumper and for bringing this incredible show to the screen!!Support the Severed Podcast on Patreon! (Click here)APPLE PODCAST LISTENERS: If you are enjoying "Severed: The Ultimate 'Severance' Podcast" please make sure to leave a 5-star rating (and, if you want, a review telling others to give it a try). Higher rated podcasts get better placement in suggestion lists. It helps more "Severance" fans find the show. Thanks!!! (Unfortunately, I can't respond to any questions or comments made in Apple Podcast Reviews. Send those to: SeveredPod@gmail.com)Season 2 of "Severance" kicked off 1/17/2025 and ran through 3/20/2025. The Second Season of the "Severed" Podcast Rewatch Episodes kicked off on April 24th, 2025. To support the Severed Podcast: (www.patreon.com/SeveredPod) Join the fun on our Facebook page @SeveredPod. I always try to keep page followers  updated on news about the show. Also, let's talk!! Comments? Theories? Corrections? I LOVE 'EM!! Send to: SeveredPod@gmail.comPLEASE MAKE SURE TO SHARE THE PODCAST WITH YOUR FRIENDS WHO ARE 'SEVERANCE' FANS. THE SHOW GROWS THROUGH WORD OF MOUTH!!Needing your own copies of the Lexington Letter and Orientation Booklet? I've got you covered with downloadable PDFs of both documents:LETTER: LEXINGTONLETTER-TheLetter.pdf HANDBOOK: LEXINGTONLETTER-MDROrientationHandbook.pdfYou haven't completely watched 'Severance' until you've listened to 'Severed'.

WBZ NewsRadio’s Chaiel Schaffel (@CSchaffelWBZ) reports.See omnystudio.com/listener for privacy information.

James Rojas reports. See omnystudio.com/listener for privacy information.

Good Vibe Tribe: Charles River Conservancy full 349 Fri, 23 Jan 2026 12:43:50 +0000 5rl96u1TeFV6mW83zfRRr0kJVHerhyml latest,wwbx,society & culture Karson & Kennedy latest,wwbx,society & culture Good Vibe Tribe: Charles River Conservancy Karson & Kennedy are honest and open about the most intimate details of their personal lives. The show is fast paced and will have you laughing until it hurts one minute and then wiping tears away from your eyes the next. Some of K&K’s most popular features are Can’t Beat Kennedy, What Did Barrett Say, and The Dirty on the 30! 2024 © 2021 Audacy, Inc. Society & Culture False https://player.amperwavepodcasting.com?feed-link=h

When you're managing $60 trillion in assets across dozens of products and 30 global jurisdictions, technical debt isn't just an inconvenience—it's an existential risk.Jason Adams, Interim CTO of Charles River, a State Street Company, leads 800 engineers building mission-critical trading platforms for the world's largest asset managers. Joined by Sid Pardeshi, Co-Founder and CTO of Blitzy, he explains how State Street is using an AI-augmented SDLC to modernize decades-old systems, refactor legacy code, and dramatically increase developer productivity—without compromising the rigor required in financial services.Jason frames the strategy around three pillars: AI for engineering (copilots and polyglot support),AI for operations (APM, observability, and proactive monitoring), andAI embedded in products (LLM-powered explainers).Using Blitzy's agentic approach—iterative context building, dependency mapping, and targeted code generation—State Street compressed months of work into weeks while maintaining strict quality gates.About the Guests:Jason AdamsJason Adams is the Interim CTO of Charles River, a State Street Company. He brings deep expertise in modernizing legacy fintech infrastructure into scalable, cloud-native systems that support mission-critical financial services at global scale.Previously, Jason was Head of Platform Product and Strategy at Charles River Development and CTO of Mercatus (acquired by State Street and now part of Charles River for Private Markets). He has led high-impact initiatives across engineering, product, and cloud infrastructure, with extensive experience guiding end-to-end delivery teams.Today, Jason is driving a comprehensive SaaS transformation at CRD, focused on building resilient, future-ready architectures. From scaling global engineering organizations to delivering secure, high-performance platforms, he is committed to advancing innovation, agility, and long-term growth across Charles River, State Street Alpha, and State Street.Sid PardeshiSid Pardeshi is a technology leader and entrepreneur, currently Co-Founder and CTO of Blitzy. He holds a Harvard MS/MBA and previously served as a Software Architect at NVIDIA, where he built deep expertise at the intersection of AI, large-scale software systems, and product innovation.At NVIDIA, Sid was recognized as a Master Inventor, earning the Inventor's Jacket for driving AI-powered product innovation, with more than 25 U.S. patents filed across gaming, augmented reality, and virtual reality. He is also a seasoned software engineer with a strong track record in application performance optimization, delivering native client load-time improvements of up to 90%.Beyond hands-on engineering, Sid has led and coordinated software design, framework requirements, and application architecture across global teams of 500+ engineers. Today, he applies this blend of innovation, technical depth, and organizational leadership to building autonomous software development platforms that help enterprises modernize at scale.Timestamps:00:30 – Jason on Managing $60 Trillion in Assets01:55 – Challenges and Strategies in Financial Services07:00 – Embracing AI for Modernization09:10 – AI in Software Development Lifecycle15:55 – Ensuring Quality and Compliance with AI23:55 – AI in Operations and Incident Response26:00 – Proactive Workflow Monitoring26:20 – AI in SDLC: Creation to Operations30:00 – Challenges in AI Recommendations33:20 – Iterative Context Building with AI36:00 – Human Side of AI Transformation42:30 – Adopting AI Tools in Financial ServicesGuest Highlights:"One of the things that excites me the most right now is the ability to use an AI-augmented SDLC to drive modernization. Otherwise, with this many systems, it's too hard." — Jason "You have to invest in the non-attractive parts first. You have to build a foundation that's gonna support being able to bring on solutions and tools that could change your overall enterprise SDLC. That's a lot of work and that's a major investment." — Jason "We are unlocking by adding these additional capabilities and additional assurance that improves quality exponentially more than we could have in the past. Now I can have an agent swarm check itself—multiple agents doing code review at a level of depth we just don't have time to get to." — JasonGet Connected:Jason Adams on LinkedInSid Pardeshi on LinkedInYousuf Kahn on LinkedInIan Faison on LinkedInHungry for more tech talk? Check out latest episodes at ciopod.com: Ep 63 - How Autonomous AI is Solving the Enterprise Modernization ChallengeEp 62 - Running IT Like a Growth EngineEp 61 - What Manufacturing Can Teach You About Scaling Enterprise AILearn more about Caspian Studios: caspianstudios.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

As we all learned in 2020, getting ahead of the next major pandemic is a matter of global concern. For the Coalition for Epidemic Preparedness Innovations, or CEPI (cepi.net), it is their reason for existing. Joining me for this conversation are Valentina Bernasconi, Head of Laboratory Science for CEPI, and Marie-Eve Poupart, Lead Scientist In Charles River's Immunology department. Together we discuss CEPI's progress so far, how Charles River is contributing to the cause, and how we can plan for the unknown Disease X while simultaneously handling current outbreaks of deadly diseases like Ebola, Marburg, Nipah virus, Lassa Fever, and chikungunya.

Bradley Jay Fills In On NightSide with Dan Rea The year 1630 marks the first time public transportation was formed in Boston. It was a ferry service initiated by the Massachusetts Bay Company that took riders across the Charles River, between what is now the North End and Charlestown. This spared the English colonists a two-day walk around Boston Harbor! Learn more about the history of Boston transit with Steven Beaucher, Cofounder and Proprietor of WardMaps LLC. See omnystudio.com/listener for privacy information.

What if we could predict how chemicals affect human lungs without using animals? In this episode of Sounds of Science, Mary McElroy, Head of Discovery Toxicology and Pharmacology at Charles River, joins us to explore a groundbreaking collaboration with MatTek Life Sciences. Together, they're pioneering human-relevant, non-animal models that could revolutionize inhalation toxicology. From 3D lung tissues to computational dosimetry, discover how science is catching its breath and moving toward a safer, more ethical future. Show NotesInhalation Toxicology | Charles River Mini Organs Offer Alternative Method for Predicting Drug Safety and Efficacy Alternative Methods Advancement Project | Charles River Charles River, in Collaboration with MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives 

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Nick Fortin, Chief Executive Officer at Codis. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Nick, covering: Nick's desire to scratch that entrepreneurial itch, while recognising he was missing a key tool in his toolbox, which led him to pursue a midlife MBA. His turnaround role at Neopharma exposed him to major players in the pharma services space, ultimately paving the way to Particle Dynamics (now Codis). The major pillars Nick established when he joined Particle Dynamics as CEO, and the company's transformational journey that led to further investment, a major international acquisition, and the creation of Codis. Key lessons on managing multiple investors around the board table — and the critical role of a Chairman. Why the bioavailability challenge for many molecules in the pipeline supports continued growth in spray drying. Nicolas joined Particle Dynamics as President and CEO in 2018. He has almost 30 years of experience in the pharmaceutical industry across multiple leadership roles. Nicolas earned a Bachelor's degree in Engineering and holds an MBA from McGill and HEC Universities. Molecule to Market is sponsored by Bora Pharma (boracdmo.com) and Charles River (criver.com), and supported by Lead Candidate. Please subscribe, share with your industry colleagues, and join us in celebrating and promoting the value of the global life sciences outsourcing space. We'd also appreciate a positive rating!

In this episode we sit down with Joe Kenny of Joe's Crazy Critters!  We found out about Joe from a recent news story about an alligator being spotted in the Charles River in Boston MA. Joe was featured on the news as a topic specialist, and shortly after the broadcast hopped in the car and went and found the alligator(now named Charles). Joe tells us how he got into exotic animals at a young age and how it quickly developed into quite a business, all stemming from a brainstorming session with his family as a child. Joe also brought it lots of amazing animals for us to meet live in the studio!  If you are looking to have exotic animals at a party, or event reach out to Joe Kenney at Joe's Crazzy (yes, with 2 Zs) Critters!

Charles River's CSO Julie Frearson outlines the FDA's planned transition away from animal testing, changing attitudes to artificial intelligence, and the move to New Alternative Methods.

A recent proposal by the Massachusetts Water Resources Authority (MWRA) would allow sewage overflows into the Charles River by declassifying it as “safe to swim,” a designation that allows the waterway to be “occasionally subject to short-term impairment of swimming or other recreational uses.” The MWRA was set to vote on the proposal but tabled the vote. It's unclear how they will proceed but advocates of keeping the Charles River, Alewife Brook, and other local waterways sewage free view the postponement as a victory. Emily Norton, the executive director of the Charles River Watershed Association joined to discuss the ongoing concerns over proposed sewage overflows into the Charles River.See omnystudio.com/listener for privacy information.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with: Andrew Gigax, Head of European Pharma Services M&A at William Blair Jennifer Chadwick, Founder and Principal at Jennifer Chadwick Consulting Sabina Ouimet Storrs, Principal at GHO Capital Partners Jason Foss, Head of Corporate Development at Bora Pharmaceuticals Your host, Raman Sehgal, speaks with his guests about the pharmaceutical and biotechnology ecosystem, including: How market stabilisation has been overtaken by the need for adaptation in times of uncertainty Disciplined and deeper M&A, with heightened scrutiny, buyer and seller disconnect, and a sharper focus on operational efficiency The growing demand for bispecifics, radiopharma, isotopes, and other emerging segments Why the “picks and shovels” that serve multiple modalities are where opportunity lies in pharma services Why the US remains the hottest market, and how AI adoption has mainly focused on workflow so far The shifts and trends that could reshape pharma services in the years ahead Molecule to Market is sponsored by Bora Pharma, Charles River and Lead Candidate, and supported by Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!

The Boston Globe's Nancy Barnes and Shirley Leung join for “Press Play" media analysis. The talk about AI in journalism, new polls about Americans' trust in media, and the 2025 Globe Summit. GBH's Callie Crossley discusses a bill on book banning, new lousy polling numbers for President Trump and Cheryl Hines' new memoir.Shelter Music Boston performs for Live Music Friday. They're celebrating 15 years of performing in local homeless shelters. We talk with founder Julie Levin, founding violist Rebecca Strauss and managing director Carrie Eldridge-DicksonNBC10 Boston's Sue O'Connell recaps her trip to Canada reporting on the Christmas tree cutting ceremony. Plus, SCOTUS declining to hear case to overturn same-sex marriage and an alligator in the Charles River.

A baby alligator was found along the Charles River and someone falls for potentially the worst scam attempt in Essex in the New England Nightly News.

With the Patriots now in action, we have some fun starting with tonight's Headlines featuring the announcement of AL and NL MVP and NFL owners deflecting blame by wanting to get rid of the NFLPA survey. Then, a baby alligator was found in the Charles River while an Essex scammer had the basic way of scamming an elderly man in the New England Nightly News. And, an update on the Patriots and Bruins who have done a great job of limiting penalties.

In this episode of Molecule to Market, your host Raman Sehgal discusses the pharmaceutical and biotechnology supply chain with Jean-François Brepson, Chief Executive Officer at PathoQuest. The conversation covers: Navigating 20 years of global leadership roles at Ipsen before moving from the corporate world into an investor-led entrepreneurial adventure The tough decision to refocus PathoQuest from diagnostics into a pure play CRO and pharma services business How a major strategic partnership transformed the company's trajectory and why Jean sees partnerships as a competitive weapon Riding the tailwind of the FDA's move away from animal testing and offering something game-changing in the CMC and GMP space The opportunities ahead for CROs and CDMOs in helping unlock the next wave of innovation Jean-François Brepson is a dedicated leader with deep experience in biotechnology and pharmaceuticals. Since becoming CEO of PathoQuest in 2015, he has built the company into a leading global CRO specializing in quality control of biological drugs using Next Generation Sequencing (NGS). Over his career, he has advanced innovative technologies and solutions that bridge scientific progress with real-world application. Prior to joining PathoQuest, Jean was Senior Vice President at Ipsen, where he led the global GI-Oncology and Endocrinology franchise.   Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!

A caller shocks everyone when he reveals he has six kids with six different women — oh, and he’s a tattoo artist.

The Bubonic Plague, Yersinia Pestis, arrives in London at the end of 1664. By the end of 1665, it will have killed 200,000 people all across England and Wales. Evelyn Lord, The Great Plague: A People's History. Dorothy Moote, The great plague: the story of London's most deadly year. Charles River, The Great Plague of London: The History and Legacy of England's Last Major Outbreak of the Bubonic Plague Rebecca Rideal, 1666: Plague, War, and Hellfire. Learn more about your ad choices. Visit megaphone.fm/adchoices

Keith Crawford, Global Head of Corporate Development and M&A at State Street Corporation Keith Crawford, Global Head of Corporate Development and M&A at State Street Corporation, brings over 20 years of expertise executing some of the most intricate custody business carve-outs in financial services. In this episode, Keith breaks down the realities of carve-out transactions—from proactive deal sourcing and dependency mapping to navigating TSAs and post-close integration. He shares hard-won lessons on avoiding common pitfalls like scope creep, third-party contract renegotiations, and employee retention challenges that can derail even the most promising deals. Things You'll Learn Why carve-out transactions demand bespoke approaches: No two deals are alike—discover how to identify the 20% of unknowns that templates can't capture and build flexibility into your diligence process. How to source carve-out opportunities proactively: Learn State Street's strategy for targeting custody business carve-outs, including the "why us" narrative and who to approach (hint: not the business unit leader). The integration secrets that prevent deal failure: From embedding integration experts early in diligence to managing employee retention and TSA timelines, Keith reveals how to align synergy assumptions with operational reality. ____________________ Share Your M&A Experience for the Chance at $500 Giftcard M&A moved fast in 2025. But what actually changed? We're collecting real insights from practitioners—not consultants on the sidelines—to understand how corp dev teams, PE firms, and advisors are adapting. Takes 10 min. Get early access to results + chance at $500 gift card. Share your experience: https://hubs.ly/Q03Rr89G0 ____________________ This episode is brought to you by S&P Global. Today's episode of M&A Science is brought to you by S&P Global Market Intelligence. If you're in corp dev or PE, you know the pain — good private company data is hard to come by. Everyone's still chasing clean, reliable, up-to-date data. I started out using CapIQ Pro for public comps, but didn't realize until recently how deep their private company coverage has gotten. Over 58 million private companies, global reach, and actually usable for real deal work.  This isn't surface-level. You get real metrics — ownership, financials, funding rounds, even asset-level insights. So if you're still toggling between a dozen tools trying to piece together the picture, maybe it's time to stop guessing and start sourcing better.  Learn More Here: https://www.spglobal.com/market-intelligence/en/solutions/products/private-company-data?utm_source=podcast&utm_medium=video&utm_campaign=MAScienceH225 _______________ Episode Chapters: [00:03:30] From Accountant to M&A Leader – Keith's journey from audit to becoming a dealmaking general contractor [00:06:00] The General Contractor Mindset – Why successful M&A requires orchestrating expert teams across tax, operations, IT, and risk [00:06:30] The 80/20 Rule of Carve-Outs – Why templates work for most deals but the 20% whitespace requires bespoke analysis [00:10:00] Third-Party Contract Landmines – How change-of-control provisions can blow up your valuation assumptions [00:16:00] Building Strategic Alignment Early – Embedding integration experts into diligence to bridge deal models with operational reality [00:23:00] Proactive Deal Sourcing Strategy – State Street's approach to targeting custody business carve-outs with a clear "why us" narrative [00:35:00] Leveraging Banker Networks Strategically – How mid-tier investment banks often have better contacts for carve-out opportunities [00:48:00] Culture Preservation in Integration – Lessons from the Charles River acquisition on maintaining employee morale and retention [00:52:30] Major Deal Breakers – The two red flags that cause State Street to walk away from carve-out transactions [00:55:00] The Craziest M&A Moment – A hospital room negotiation that almost derailed a major international carve-out ____________________ Questions, comments, concerns?Follow Kison Patel for behind-the-scenes insights on modern M&A.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jason Anderson, Chief Executive Officer at Ensera.   Your host, Raman Sehgal, speaks with Jason about the pharmaceutical and biotechnology supply chain, covering: Why he chose BASF over law school, and why McKinsey ultimately was not for him Moving from corporate life into a venture-backed polymer technology start-up before a major exit The search for a PE-backed specialty manufacturing role that led him to Ensera (formerly SteriPack) The importance of appreciating local knowledge when entering new markets Similarities and differences between outsourced services in pharma and medical devices How today's changes, pain, and uncertainty in the markets are creating opportunity Jason Anderson is CEO of Ensera (formerly SteriPack), a global contract design and manufacturing organization serving the pharmaceutical and medical device industries. He has led the company through a period of significant growth and change, including the integration of new design and product development capabilities with Ensera's core manufacturing services, and the launch of the new Ensera trading name.   Prior to Ensera, Jason held global business unit leadership roles at DJO/Enovis and at Saint-Gobain, overseeing businesses ranging from finished medical devices to customized, high-value components for biopharma and medical device industries. Earlier in his career, he held leadership roles at pre-revenue polymer technology start-up Novomer, at McKinsey and Company, and at BASF.   Jason has lived and worked in North America, Asia, and Europe. He holds a BS in Chemical Engineering from the University of Oklahoma and an MBA from Harvard Business School.   Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!

Charles River scientist Nicole Hoekstra, herself a US Navy veteran, used her employer-supported sabbatical to help out local Oklahoma based nonprofit Inner Circle Mental Health, which focuses on aiding veterans and first responders who are struggling with their mental health. I am joined by Nicole and ICMH founder Kate Cooper to discuss what this service means to both of them, how we can support family who are reluctant to accept help, and how the COVID pandemic impacted the mental health of first responders. 

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with our host Raman Sehgal, who discusses the themes and vibe of CPHI 2025 in Frankfurt.     Molecule to Market is also sponsored by Bora Pharma and Charles River, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Molecule to Market, you'll hear wily old wisdom, golden nuggets and invaluable insider tips about CPHI. The nuanced stuff from Veterans of CPHIs gone by you'll never find in a generic AI-written playbook. The show features: James West, Managing Director, Bourne Partners Arul Ramadurai, CCO at Axplora Christine Fuerst, Director Key Account Management Europe, Vetter Pharma International GmbH Dan Stanton, leading pharma/biopharma industry journalist  Jeremy Drummond PhD, retired VP Sales and Marketing Exec.   Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Gil Roth, President, at Pharma & Biopharma Outsourcing Association (PBOA). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gil, covering: How planned FDA budget cuts and the ongoing US government shutdown are impacting the industry. And the potential outlook if those issues remain unresolved... Why positive early-phase clinical trial activity could signal a stronger year ahead Real-life applications of AI and machine learning for GMP in CDMOs through signal and pattern recognition Why Gil is feeling more optimism across the CDMO community And yes… you can also see Gil and Raman together on stage at the industry's very own “Super Bowl” of conferences Gil Roth is the Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA), a nonprofit trade group that advocates for the regulatory, legislative and general business interests of the CMO/CDMO sector. In this role, he brings CDMO perspectives and education to FDA, the US Congress, and other bodies, and brings CDMOs together to share best practices, develop policy positions, and provide briefings on government positions that impact that sector. He also organizes and hosts PBOA's annual members-only Meeting & Conference. Previously, he was the Founding Editor of Contract Pharma magazine. In his alleged free time, he produces a weekly cultural conversation podcast called The Virtual Memories Show (https://chimeraobscura.com/vm).   Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with JB Agnus, Chief Commercial Officer at Bora Pharmaceuticals. Your host, Raman Sehgal, speaks with JB about the pharmaceutical and biotechnology supply chain, including: How his global roles taught him the importance of bridging cultures What attracted him to Bora Pharmaceuticals and the company's remarkable trajectory The value of intentionality, taking charge of your own career, and prioritising physical and mental wellness What it really looks and feels like to be a CDMO CCO, and the realities of stepping up into the role Why it matters not to conform to the norm and instead stay true to yourself Prior to joining Bora, JB held senior leadership roles in business development at AGC Biologics, Ajinomoto Bio Pharma Services, Novasep, and Isochem. He holds a bachelor's degree in organic chemistry from Université Paul Sabatier Toulouse III in Toulouse, France, and a master's degree in chemical engineering from Centrale Méditerranée in Marseille, France.   Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!

In 2025, the Head of the Charles regatta celebrates 60 years - so we thought it was a perfect opportunity to reflect and look ahead at this event that brings together thousands of rowers and fans to the shores of the Charles River in Boston. We're incredibly honored to talk with D'Arcy MacMahon, one of three original founders of the regatta AND Fred Schoch, whose tenure as regatta executive director stretched 33 years. We've paired these two legends together to explore the vision of the founders and the stewardship of that vision over the last six decades. QUICK LOOK 00:00 - Episode intro and welcome 03:53 - Rowing Week 05:41 - The Huddle 08:22 - Hot Seat Q&A 13:24 - D'Arcy's fun childhood racing at CBC was the inspiration for HOCR 16:44 - Fred's youth was dominated by time at the Princeton boathouse where his Dad was coach 19:22 - D'Arcy and Fred are no strangers to racing at HOCR 22:46 - The true life (and death) story of a made up man: Charles Attager 25:14 - D'Arcy is dumbfounded by the longevity and growth of HOCR 30:23 - On carrying the legacy forward 32:30 - Setting the course in 1965 with D'Arcy's mom's bike odometer 36:36 - Volunteer spirit of service (starts with a great t-shirt) 39:12 - Support from the MDC, Massachusetts, and corporate sponsors 42:18 - Getting results: taking a cue from golf's leaderboards  43:39 - HOCR and the community 45:40 - Growing the  international field, and considering travel logistics for all crews 50:38 - Best place to watch the races 52:05 - Head of the Charles Charity 52:49 - Spirit of the regatta: fun! 54:24 - Steady State Network news and notes . To see photos of D'Arcy, Fred, and the Head of the Charles, and get links to the people, clubs, and events mentioned in this episode, check out the show notes on our website. . This episode was made possible in part by Breakwater Realty, RowSource, and our Supporters. . Steady State Podcast is hosted and edited by Rachel Freedman and Tara Morgan. Tara provides additional audio engineering, books show guests, and is our sponsor and donor coordinator. Rachel writes our scripts and e-newsletter, and manages the website and social media. Our theme music is by Jonas Hipper. . SHOP SSN GEAR: www.steadystatenetwork.com/shop SIGN UP FOR THE SSN NEWSLETTER: www.steadystatenetwork.com/newsletter MAKE A DIFFERENCE: www.steadystatenetwork.com/support  Check out more Steady State Network here:  FB - /SteadyStateNetwork IG - @SteadyStateNetwork BLUESKY - steadystatenetwork.bsky.social FB - /AllieswithOars IG - @AllieswithOars Connect on FB and IG with the hosts: Rachel Freedman - @RowSource Tara Morgan - @CmonBarber

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Philip Macnabb, Chief Executive Officer at Curia. Your host, Raman Sehgal, speaks with Phil about the pharmaceutical and biotechnology supply chain, covering: Over 25 years of working with private equity — and why PE is ultimately about building sustainable value. The common threads he looks for as a CEO of any new organisation, and why employees often know the answer first. Navigating the COVID comedown at Curia, making major network changes, and refocusing on biotech clients. Why CDMOs are really selling trust as the service, not just manufacturing — and how that plays into customer intimacy and reputation. Betting on the trend toward small batch sizes and personalised medicines in biotech and pharma. Phil leads Curia in pursuit of its mission to improve patients' lives, applying end-to-end capabilities and deep scientific expertise to advance customers from idea to impact. He brings more than 20 years of private-equity leadership experience to Curia, including the last decade in healthcare. Most recently, he served as Chief Executive Officer at Epsilon Global, a company he co-founded. In addition to his healthcare experience, he has held senior positions in technology, distribution, and consumer products. Phil has a proven track record of sharpening companies' core value proposition, enhancing the customer experience, and building organisations with real, lasting value. Phil earned an MBA from the University of Chicago and a BS in Business Administration from Purdue University.   Molecule to Market is sponsored by Bora Pharma and Charles River, and supported by Lead Candidate. Please subscribe, tell your colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Lars Petersen, President & Chief Executive Officer at FUJIFILM Biotechnologies.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Lars, covering: The difficult decision to leave Novo Nordisk and make the jump from one great company to another in Genentech/Roche. How leaving a Biogen site led him to step away from big pharma after 25 years and transition to the CDMO side. How Fujifilm's culture of innovation, technology, quality, and people runs through the Biotechnologies division — and why empowerment and culture should never be compromised. Why the duplication of its CDMO sites globally, all running on the same kojoX platform, is truly differentiating. Why he believes the need to standardise, scale, and globalise drug production in a consistent, efficient, and traceable way is key to the future of the supply chain. Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by Lead Candidate.    Lars Petersen, CEO of FUJIFILM Biotechnologies, is recognized as a visionary leader in the life science sector, commanding a global contract development and manufacturing organization (CDMO) with nearly 5,000 employees spread across Denmark, UK, USA, and Japan.    Distinguished for his strategic vision and a "people first" philosophy, Lars has profoundly impacted the company and the industry. His leadership journey saw him rise from Chief Operational Officer & Senior Vice President at the Danish site, where he established an empowering culture, to CEO, promoting transparency across all operations. Since his global leadership appointment in June 2023, Lars has been instrumental in cultural transformation, integrating a "people first" approach across FUJIFILM Biotechnologies' global facilities regardless of geographical differences.   Prior to his appointment as CEO, Lars was responsible for the Global Large Scale Commercial operation including full profit and loss accountability as well as the responsibility for over $6.2 Billion global expansions both in Hillerød, Denmark, and Holly Springs, North Carolina, USA.   Previously, Lars has held leadership positions with Biogen, Genentech/Roche, Novo Nordisk, Novozymes and NNE, and he has successfully executed projects in Europe, China and the US.   Lars holds a master's degree from the Technical University of Denmark.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! 

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Matt Lowe, CEO at performance.io/ Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Matt, covering: Seeing a niche in SEO, within the healthcare space... and opting to take a risk and jump our of big pharma. Why healthcare agency models are built for agencies, not pharma. The mass wastage of big pharma spend when it comes to the commercial launch. How you should be thinking about generative search and customer experience... and why Google is still dominating the search landscape. Founder and CEO at performance-io (PIO), Matt has been the driving force behind bringing search engine optimization (SEO) into pharma. With more than 22 years in the highly regulated industry pharma space, spanning client-side and agency roles, he is responsible for a number of industry firsts, all focused on helping pharma companies to revolutionize their customer engagement.   Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Michael Scholl, Chief Executive Officer and Co-Founder at Leukocare. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Michael, covering: The influences, and potential for impact that led him down a path of entrepreneurship. Chronicling the ups and downs of over 20 years in business at Leukocare. Pivoting to be a specialist CRO/CDMO with a differentiation in data-driven, formulation development... leading to a record year in 2024. How the delay in decision making in the market is impacting the pharma services space. Michael Scholl is the Co-founder and Chief Executive Officer of Leukocare, a leading CDMO specializing in formulation and drug product development services for sterile injectables. With more than 20 years of leadership experience in the life sciences industry, Michael is responsible for shaping the company's strategic direction and cultivating partnerships with biopharmaceutical clients around the world. Under his leadership, Leukocare has established itself as a trusted partner in advancing complex biologics from early development to market-ready drug products. He began his career as a business consultant at the Boston Consulting Group (BCG), he holds a degree in Industrial Engineering from the Technical University of Berlin and studied at the Haas School of Business, University of California, Berkeley.   Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Kaan-Fabian Kekec, Partner in Healthcare and Life Sciences at Simon-Kucher. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kaan, covering: Being on the sunny side of consulting, and helping clients unlock growth. What makes a key strategic partnership both from a CDMO, and a sponsor perspective. The taboo subject of pricing and how it can be used to help unlock commercial positioning, and excellence. Common mistakes in BD teams, and the importance of value positioning. The hottest segments in the market right now, and some of the competitive drivers in today's market. Kaan leads the firm's Healthcare B2B and Pharma Services business globally, encompassing CDMOs, CROs, bioprocessing solutions, drug delivery, packaging, and more. He specializes in delivering end-to-end commercial strategies for CDMOs, advising on growth initiatives and supporting clients throughout the entire lead-to-deal process—from marketing and sales to proposal management and deal optimization. Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.  Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Boston is one of those cities that just gets under your skin in the best way possible. Equal parts old-school history and modern-day hustle, it's where cobblestone streets meet glass skyscrapers, where the story of America was born, and where you can eat your body weight in lobster rolls without a shred of regret.Founded in 1630 by English Puritans, Boston has played host to some of the most pivotal events in U.S. history—the Boston Tea Party, the Battle of Bunker Hill, and even the first public park in America. Today, it's a vibrant mix of college-town energy, cutting-edge innovation, and diehard sports fandom (you'll never hear a “Go Sox!” shouted with more passion than here).I recently spent five days exploring Boston like a local, armed with a loose plan, comfy walking shoes, and an appetite big enough to conquer the city's legendary food scene. Here's how it all went down—my perfect Boston adventure. Day 1: Arrival & First Taste of the CityFlying into Logan International Airport is a breeze—it's practically right in the city. But here's your first Boston pro-tip: skip renting a car if you can. Boston traffic is next-level chaotic, parking is expensive, and the city is surprisingly walkable. Between the subway (locals call it “the T”) and Uber, you'll get around just fine.Of course, I had to test the rental car waters—$368 for two days of a Nissan Rogue—and let me tell you, the line alone made me question my life choices. If you do rent, book with a company that lets you walk straight to the garage and grab your car. Otherwise, hop in an Uber and save yourself the headache.Where to StayI split my stay between two totally different vibes:Hampton Inn & Suites Watertown – Budget-friendly ($100 a night) and great if you don't mind being just outside the city. Parking in Boston can run you $30 a day, so staying here helped balance the budget.Copley Square Hotel (FOUND Hotels) – Right in the heart of Back Bay, this historic gem ranges from $300–$600 a night. My corner-view studio overlooked the breathtaking Trinity Church at sunset, and it felt like waking up inside a postcard. Designed in 1877 by architect H.H. Richardson, this place is dripping with Richardsonian Romanesque charm—arched windows, rough stone, and colorful details. Around Copley, you'll also find:Fairmont Copley Plaza (1912) – A Gilded Age beauty and part of the Historic Hotels of America.Boston Public Library McKim Building (1895) – A Renaissance Revival masterpiece with white marble halls and free daily tours at 2 pm. Don't skip it; the architecture is jaw-dropping.Old South Church (1873) – A National Historic Landmark in Northern Italian Gothic style, complete with multicolored stone and a towering bell.John Hancock Tower (1976) – Boston's tallest skyscraper at 790 feet, shimmering in blue glass.After a long travel day, we celebrated our first night with dinner at Lolita Cocina & Tequila Bar. Order the lobster guacamole and grilled elote—and when in Boston, remember the golden rule: always order seafood. Steaks are for later. Oh, and if you see Scrod on the menu? Don't panic. It's not a weird mythical fish; it's just the white catch of the day—usually cod or haddock. Day 2: Walking Through HistoryIf Boston had a greatest hits album, it would be the Freedom Trail—a 2.5-mile path that connects 16 historic sites and tells the story of America's revolution. You can do it self-guided, join a regular tour, or go all out with an actor-led adventure (think Paul Revere cosplay).Morning Coffee & Boston CommonStart with caffeine at Thinking Cup Coffee Bar, then wander into Boston Common, the oldest public park in America (1634). It's massive, filled with monuments, and now home to the striking Embrace Memorial, honoring Martin Luther King Jr.From there, the trail unfolds like a time machine:Massachusetts State House (1798) – Charles Bulfinch's golden-domed wonder, still home to the state government.Park Street Church (1809) – Once Boston's tallest landmark, it sits on the site of the city's old grain storage.Granary Burying Ground (1660) – Final resting place of heavyweights like John Hancock, Sam Adams, and Paul Revere.King's Chapel & Burying Ground (1686) – Boston's first Anglican church, with over 330 years of history.Boston Latin School Site (1635) – The oldest public school in America; today it's marked by a Benjamin Franklin statue.Old Corner Bookstore (1718) – Once the publishing hub of legends like Hawthorne, Longfellow, and Thoreau. Now… a Chipotle (I wish I were kidding).Lunch at Union Oyster HouseBy now, you'll be starving. Enter Union Oyster House, America's oldest continuously operating restaurant (since 1826). The JFK booth is a must-sit, and yes—you're ordering a lobster roll.Afternoon: Monuments & Baseball MagicDon't miss the New England Holocaust Memorial—six glass towers etched with survivor stories, both sobering and moving.Then, if you're lucky enough to visit in season, cap off your night at Fenway Park. Whether it's catching a Red Sox game, snagging early batting practice passes, or just soaking up the energy at Cask 'n Flagon across the street (hot tip: persistence pays when getting a table here), Fenway is pure Boston. Day 3: More Freedom Trail & North End TreatsStart with breakfast at Quincy Market, the ultimate food hall. Then dive back into history:Old South Meeting House (1729) – Where colonists debated tea taxes and kicked off the Boston Tea Party.Old State House (1713) – Boston's oldest public building, central to colonial politics.Boston Massacre Site (1770) – A simple cobblestone marker for one of America's darkest sparks of revolution.From here, pop back into Quincy Market for another lobster roll (yes, it's worth a second one).Keep following the trail:Faneuil Hall (1742) – “Cradle of Liberty” where fiery speeches once filled the air. Today, it's mostly a giant souvenir shop, but the echoes of history remain.Paul Revere House (1680) – The patriot's humble home. Tours are intimate but no photos allowed inside.Old North Church (1723) – Where lanterns signaled “One if by land, two if by sea.” Take the tour to see the crypt and bell chamber.Cannoli TimeBoston's North End is an Italian dreamland, so refuel at Mike's Pastry with a giant cannoli. (Pro tip: get a few extra to-go. You'll thank me later.)End the night at Bell in Hand Tavern (1795), America's oldest continuously operating tavern. It's rowdy, it's historic, and it's the perfect spot for your nightcap. Day 4: Big Battles & Big ShipsIf your legs aren't jelly yet, tackle the Bunker Hill Monument. Climb the 294 steps for killer views of the city.From there, wander over to the USS Constitution, aka “Old Ironsides,” the oldest commissioned warship afloat. The ship and museum are free and make for an epic history-meets-maritime adventure.For a modern twist, hop in an Uber to the JFK Presidential Library & Museum—a sleek, inspiring deep dive into the Camelot era. Afterward, head to Sam Adams Brewery in Jamaica Plain. Tours start at $10, include tastings, and give you all the Boston beer vibes. Day 5: Art, Rainy-Day Magic & Sunset on the HarborBoston weather can turn on a dime, so I saved indoor treasures for day five.Morning: Museum of Fine ArtsThe MFA is massive, so choose wisely:Jewelry lovers: Beyond Brilliance exhibit (ancient to modern sparkle, with Chanel and Bulgari highlights).Classicists: Greek, Roman, and Byzantine collections.Painters-at-heart: Dutch & Flemish gallery with works by Rembrandt and Rubens.Quirky souls: Dollhouses and temporary Van Gogh exhibits.Fuel up at the museum café before heading out.Evening: Sunset Harbor CruiseOur trip ended on the water, with a Boston Harbor sunset cruise. Even in the rain, the top deck views were worth it. There's a buffet dinner, DJ, and plenty of space to dance—because no Boston trip is complete without one last celebration. Other Boston Must-Dos (If You Have Time)Duck Boat Tour – Amphibious buses that roam the streets then splash into the Charles River. Cheesy? Yes. Fun? Also yes.Cheers Pub – Grab a drink where everybody used to know your name.Green Dragon Tavern – A revolutionary haunt turned modern-day pub.Boston Burger Co. or Wahlburgers – Because you need at least one outrageous burger on this trip. Final ThoughtsBoston is the kind of city that can be done in a weekend but deserves a week. It's history you can touch, seafood you'll crave long after, and neighborhoods that feel like they've been waiting just for you.If you only had one day, I'd say walk the Freedom Trail—it's Boston in a nutshell. But if you want to experience the city like a local? Take your time, eat the lobster rolls, get lost in the cobblestone streets, and maybe—just maybe—let Fenway turn you into a Red Sox fan for life.Boston, you're wicked awesome.